Elucidation of this metabolic regulatory network provides theoretical foundation for combination therapies targeting PI3K–AKT–mTOR pathway inhibitors, with preclinical studies confirming their ability to significantly sensitize tumor cells to FINs. The gene discussed is AKT1; the disease is neoplasm.